INM: InMed Pharmaceuticals Inc. Stock

by  •  • Comments Off on INM: InMed Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.31
Enterprise Value ($M) -0.11
Book Value ($M) 6.18
Book Value / Share 5.12
Price / Book 0.54
NCAV ($M) 3.15
NCAV / Share 2.61
Price / NCAV 1.05

Profitability (mra)
Return on Invested Capital (ROIC) -1.11
Return on Assets (ROA) -0.52
Return on Equity (ROE) -0.62

Liquidity (mrq)
Quick Ratio 2.44
Current Ratio 3.05

Balance Sheet (mrq) ($M)
Current Assets 5.47
Assets 8.50
Liabilities 2.32
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 4.60
Operating Income -8.13
Net Income -7.68

Cash Flow Statement (mra) ($M)
Cash From Operations -6.99
Cash from Investing -0.01
Cash from Financing 4.65

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Armistice Capital, Llc 4.99 14.86
11-12 13G AdvisorShares Trust 8.77

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-09-30 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT T
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-10 12,093 36,691 32.96
2025-03-07 7,037 15,655 44.95
2025-03-06 3,119 11,731 26.59
2025-03-05 5,149 35,482 14.51

(click for more detail)

Similar Companies
INAB – IN8bio, Inc. INDP – Indaptus Therapeutics, Inc.
INKT – MiNK Therapeutics, Inc. INMB – INmune Bio, Inc.
INO – Inovio Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io